MedTrace Logo

TCR-T Cells in the Treatment of Advanced Pancreatic Cancer

NCT06054984 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-10-13

No results posted yet for this study

Summary

To investigate the safety, tolerability, efficacy and pharmacokinetics of TCR-T cells in the treatment of advanced pancreatic cancer

Conditions

Interventions

DRUG

TCR-T Cells Injection（GB3010 Cells Injection）

The TCRT cells used in this clinical trial were derived from the patient's autologous peripheral-blood T cells and were genetically transduced to express a T-cell Receptor that recognizes the RAS/TP53.Patients were sequentially enrolled into 3 dose escalation groups(dose level 1-3) :5×10\^8±20%,5×10\^9±20%,5×10\^10±20%.

Sponsors & Collaborators

  • Shanghai Essight Bio Co.,Ltd

    collaborator UNKNOWN

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • BoYongShen · Ruijin Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-07
Primary Completion
2024-06-07
Completion
2024-09-07

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06054984 on ClinicalTrials.gov